A1M Pharma AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
|
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 29Cr 2.79Cr 233.58Cr |
---|---|---|---|---|---|
Net income 2024 * | -9.9Cr -94.17L -79Cr | Net income 2025 * | -9.9Cr -94.17L -79Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | 10Cr 98.93L 83Cr | Net cash position 2025 * | 50L 5L 3.98Cr | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.33
x | P/E ratio 2025 * |
-4.33
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 01/18/01 | |
Karin Botha
DFI | Director of Finance/CFO | 51 | 14/20/14 |
Michael Reusch
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Johan Bygge
CHM | Chairman | 68 | 01/21/01 |
Göran Forsberg
BRD | Director/Board Member | 61 | 29/19/29 |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 01/22/01 |
1st Jan change | Capi. | |
---|---|---|
+38.36% | 5.27TCr | |
+38.71% | 3.9TCr | |
-8.63% | 3.85TCr | |
+25.46% | 3.04TCr | |
-11.17% | 2.64TCr | |
+11.44% | 2.61TCr | |
+45.09% | 1.42TCr | |
+32.93% | 1.26TCr | |
-5.30% | 1.15TCr |